BioStock: Covid unmasks need for better mental health medication

As researchers continue working around the clock to put together the puzzle pieces needed for better understanding Covid-19 pathology, the disease has further exposed a serious lack of treatments for mental health conditions. In Sweden, biotech Gabather is developing new treatments for CNS diseases, including psychiatric disorders that appear in many Covid-19 patients. BioStock got in touch with Gabather’s CEO Dr Michael-Robin Witt, to learn more about how the company’s lead candidate GT-002 could help reduce the Covid-related mental health burden.

Read the full interview with Michael-Robin Witt at biostock.se:

https://www.biostock.se/2021/05/covid-unmasks-need-for-better-mental-health-medication/

This is a press release from BioStock - Connecting Innovation & Capital.